Table 1 Baseline characteristics of patients according to TyG index levels
Variable | Total | TyG index level | P value | ||
|---|---|---|---|---|---|
T1 (≤ 8.5) | T2 (> 8.5, ≤ 8.95) | T3 (> 8.95) | |||
N (%) | 652 | 217 | 223 | 212 | - |
Age, y | 58.2 ± 10.49 | 59.1 ± 10.78 | 58.5 ± 10.33 | 56.9 ± 10.29 | 0.069 |
Male, n (%) | 546(83.7) | 189(87.1) | 188(84.3) | 169(79.7) | 0.113 |
BMI, kg/m2 | 26.0 ± 3.19 | 25.2 ± 3.06 | 26.2 ± 3.06 | 26.7 ± 3.30 | < 0.001 |
Heart rate, bpm | 72.22 ± 10.60 | 71.11 ± 10.04 | 72.43 ± 11.37 | 73.13 ± 10.26 | 0.133 |
SBP, mmHg | 128.34 ± 17.32 | 126.41 ± 17.49 | 128.02 ± 17.60 | 130.66 ± 16.66 | 0.037 |
Medical history and risk factors, n (%) | |||||
Current smoker | 238(36.5) | 84(38.7) | 75(33.6) | 79(37.3) | 0.522 |
Hypertension | 431(66.1) | 121(55.8) | 155(69.5) | 155(73.1) | < 0.001 |
Diabetes | 240(36.8) | 53(24.4) | 71(31.8) | 116(54.7) | < 0.001 |
Dyslipidemia | 481(73.8) | 153(70.5) | 163(73.1) | 165(77.8) | 0.217 |
Previous MI | 108(16.6) | 33(15.2) | 39(17.5) | 36(17.0) | 0.797 |
Previous Stroke | 37(5.7) | 14(6.5) | 17(7.6) | 6(2.8) | 0.081 |
Previous PCI | 172(26.4) | 61(28.1) | 57(25.6) | 54(25.5) | 0.778 |
Previous CABG | 32(4.9) | 9(4.1) | 14(6.3) | 9(4.2) | 0.505 |
Laboratory Tests | |||||
eGFR, ml/min/1.73m2 | 126.53 ± 32.44 | 132.30 ± 39.25 | 122.95 ± 25.59 | 124.38 ± 30.49 | 0.005 |
FBG, mmol/L | 6.16 ± 1.36 | 5.5979 ± 0.93 | 6.0504 ± 1.03 | 6.86 ± 1.69 | < 0.001 |
TC, mmol/L | 4.01 ± 1.05 | 3.72 ± 0.98 | 3.86 ± 0.86 | 4.45 ± 1.15 | < 0.001 |
TG, mmol/L | 1.28(0.93, 1.76) | 0.84(0.70, 0.97) | 1.30(1.15, 1.50) | 2.05(1.74, 2.54) | < 0.001 |
LDL-C, mmol/L | 2.39 ± 0.86 | 2.21 ± 0.85 | 2.33 ± 0.75 | 2.62 ± 0.93 | < 0.001 |
TyG index | 8.8 ± 0.57 | 8.2 ± 0.25 | 8.7 ± 0.13 | 9.4 ± 0.43 | < 0.001 |
ACS type, n (%) | |||||
Unstable angina | 567(87.0) | 185(85.3) | 194(87.0) | 188(88.7) | 0.574 |
AMI | 78(12.0) | 29(13.4) | 26(11.7) | 23(10.8) | 0.714 |
Medication at discharge, n (%) | |||||
Aspirin | 640 (98.2) | 214(98.6) | 219(98.2) | 207(97.6) | 0.752 |
clopidogrel | 426(65.3) | 142(65.4) | 147(65.9) | 137(64.6) | 0.960 |
ticagrelor | 226(34.7) | 75(34.6) | 76(34.1) | 75(35.4) | 0.960 |
statin | 639(98.0) | 214(98.6) | 216(96.9) | 209(98.6) | 0.321 |
Ezetimibe | 134(20.6) | 37(17.1) | 44(19.7) | 53(25.0) | 0.117 |
Any antidiabetic agents | 167(25.6) | 31(14.3) | 49(22.0) | 87(41.0) | < 0.001 |
Angiographic Coronary anatomy, n (%) | |||||
Any left main disease | 150(23.0) | 53(24.4) | 53(23.8) | 44(20.8) | 0.629 |
Multivessel disease | 392(60.1) | 125(57.6) | 121(54.3) | 146(68.9) | 0.005 |
Lesions > 20 mm | 295(45.2) | 81(37.3) | 104(35.3) | 110(51.9) | 0.009 |
Ostial lesion | 70(10.7) | 28(12.9) | 23(10.3) | 19(9.0) | 0.406 |
Bifurcation | 20(3.1) | 8(3.7) | 6(2.7) | 6(2.8) | 0.808 |
Treated vessel, n (%) | |||||
LM | 61(9.4) | 24(11.1) | 21(9.4) | 16(7.5) | 0.458 |
LAD | 415(63.7) | 148(68.2) | 141(63.2) | 126(59.4) | 0.166 |
LCX | 264(40.5) | 96(44.2) | 90(40.4) | 78(36.8) | 0.291 |
RCA | 316(48.5) | 91(41.9) | 115(51.6) | 110(51.9) | 0.062 |
Mean stent diameters, mm | 2.9 ± 0.40 | 2.8 ± 0.38 | 2.9 ± 0.38 | 2.9 ± 0.42 | 0.490 |
Total length of stents, mm | 50(29,71) | 50(28,69.5) | 51(29,71) | 50(20,74) | 0.872 |
Treatment of CTO lesions, n (%) | |||||
LAD | 251(38.5) | 92(42.4) | 77(34.5) | 82(38.7) | 0.237 |
LCX | 186(28.5) | 72(33.2) | 66(29.6) | 48(22.6) | 0.049 |
RCA | 227(34.8) | 57(26.3) | 84(37.7) | 86(40.6) | 0.004 |
Successful CTO PCI | 503(77.1) | 169(77.9) | 165(74.0) | 169(79.7) | 0.346 |
Mean stent diameters at CTO lesion, mm | 2.8 ± 0.38 | 2.8 ± 0.37 | 2.8 ± 0.38 | 2.8 ± 0.40 | 0.340 |
Total length of stents at CTO lesion, mm | 40(26,66) | 40(28,65) | 38.5(25.25,64.75) | 45(28.5,68) | 0.768 |